Redeye’s first comments on CellaVision’s report for the Q4. The report showed sales lower than expected at SEK 131m vs. our SEK 139m. The gross margin was slightly lower at 66% compared with the 66.5% expected. The deviation in sales was a bit larger than we had hoped for, but we are encouraged that the gross margins hold up well. The long term prospects are still excellent, and the situation seems to be stabilizing.